Long-term follow-up of basal cell carcinomas treated with perilesional interferon alfa 2b as monotherapy
Authors:
- Jerry W. PolasekJPJerry W. Polasek
- Anthony J. PerriAPAnthony J. Perri
- Elizabeth A. GoldsmithEGElizabeth A. Goldsmith
- 1 June 2006
- journal article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 54 (6) , 1033-1038
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Basal cell carcinomaBMJ, 2003
- The Management of Melanoma and Nonmelanoma Skin Cancer: A Review for the Primary Care PhysicianMayo Clinic Proceedings, 2001
- Use of Recombinant Interferon Alfa-2b in the Treatment of Basal Cell CarcinomaDermatology, 1995
- Treatment of Basal Cell Carcinoma with Intralesional Interferon Alpha-2bJournal of the Royal Society of Medicine, 1991
- Intralesional Alpha 2b Recombinant Interferon for Basal Cell CarcinomasInternational Journal of Dermatology, 1991
- Histologic pattern analysis of basal cell carcinomaJournal of the American Academy of Dermatology, 1990
- Intralesional interferon-alpha 2b treatment of basal cell carcinoma.Acta Dermato-Venereologica, 1990
- Intralesional interferon therapy for basal cell carcinomaJournal of the American Academy of Dermatology, 1990
- Long‐Term Recurrence Rates in Previously Untreated (Primary) Basal Cell Carcinoma: Implications for Patient Follow‐UpThe Journal of Dermatologic Surgery and Oncology, 1989
- Treatment of basal cell carcinoma with intralesional interferonJournal of the American Academy of Dermatology, 1986